Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
PLRX logo PLRX
Upturn stock ratingUpturn stock rating
PLRX logo

Pliant Therapeutics Inc (PLRX)

Upturn stock ratingUpturn stock rating
$1.16
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: PLRX (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

13 Analysts rated it

Well-followed company, solid analyst reports, reliable data for confident investing.

1 Year Target Price $4.79

1 Year Target Price $4.79

Analysts Price Target For last 52 week
$4.79Target price
Low$1.1
Current$1.16
high$16.1

Analysis of Past Performance

Type Stock
Historic Profit -42.8%
Avg. Invested days 19
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 76.73M USD
Price to earnings Ratio -
1Y Target Price 4.79
Price to earnings Ratio -
1Y Target Price 4.79
Volume (30-day avg) 13
Beta 1.36
52 Weeks Range 1.10 - 16.10
Updated Date 06/30/2025
52 Weeks Range 1.10 - 16.10
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -3.61

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -33.89%
Return on Equity (TTM) -63.22%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -168124290
Price to Sales(TTM) 3071.82
Enterprise Value -168124290
Price to Sales(TTM) 3071.82
Enterprise Value to Revenue 1376.69
Enterprise Value to EBITDA -2.54
Shares Outstanding 61386300
Shares Floating 54119370
Shares Outstanding 61386300
Shares Floating 54119370
Percent Insiders 3.04
Percent Institutions 101.02

Analyst Ratings

Rating 4
Target Price 4.79
Buy 1
Strong Buy 1
Buy 1
Strong Buy 1
Hold 11
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Pliant Therapeutics Inc

stock logo

Company Overview

overview logo History and Background

Pliant Therapeutics, Inc. was founded in 2015. It is a clinical-stage biotechnology company focused on discovering and developing novel therapeutics for fibrotic diseases.

business area logo Core Business Areas

  • Integrin Program: Development of small molecule integrin inhibitors to target fibrotic diseases.
  • Thrombospondin-1 (TSP1) Program: Development of therapeutics targeting TSP1 pathways for fibrotic diseases.

leadership logo Leadership and Structure

Dr. Bernard Coulie is the President and CEO. The company has a board of directors overseeing its operations.

Top Products and Market Share

overview logo Key Offerings

  • Bexotegrast: An oral, selective inhibitor of u03b1vu03b26 integrin. It is being developed for the treatment of idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). There is no revenue from this product yet as it is in clinical development. Competitors include Boehringer Ingelheim and Roche.

Market Dynamics

industry overview logo Industry Overview

The industry focuses on developing therapies for fibrotic diseases, characterized by excessive scar tissue formation. This is a growing market due to the increasing prevalence of these diseases.

Positioning

Pliant Therapeutics is positioned as an innovative company developing novel small molecule therapeutics targeting integrins to address unmet needs in fibrotic diseases.

Total Addressable Market (TAM)

The TAM for fibrotic disease therapies is estimated to be in the billions of dollars. Pliant Therapeutics aims to capture a significant share by offering targeted therapies with potentially improved efficacy and safety profiles.

Upturn SWOT Analysis

Strengths

  • Novel integrin-targeting platform
  • Strong preclinical and clinical data
  • Experienced management team
  • Partnerships with leading research institutions

Weaknesses

  • Clinical stage company with no approved products
  • High cash burn rate
  • Dependence on clinical trial success
  • Limited revenue streams

Opportunities

  • Expanding pipeline to address other fibrotic diseases
  • Potential for breakthrough therapies
  • Strategic collaborations with pharmaceutical companies
  • Positive clinical trial results driving market value

Threats

  • Clinical trial failures
  • Competition from established pharmaceutical companies
  • Regulatory hurdles
  • Patent challenges

Competitors and Market Share

competitor logo Key Competitors

  • BIIB
  • GILD
  • NVO

Competitive Landscape

Pliant is competitive due to its novel small molecule approach targeting integrins, while large pharmaceutical companies have greater resources and market reach.

Growth Trajectory and Initiatives

Historical Growth: Growth is measured by the advancement of clinical trials and potential indication expansion.

Future Projections: Future growth depends on the success of Bexotegrast and other pipeline assets in clinical trials.

Recent Initiatives: Initiatives focus on advancing clinical trials for Bexotegrast in IPF and PSC and expanding the pipeline.

Summary

Pliant Therapeutics is a clinical-stage biotech company with a novel approach to treating fibrotic diseases. Its strengths lie in its innovative technology and experienced team, while its weaknesses include being pre-revenue and reliant on clinical trial success. Opportunities include expanding the pipeline and strategic partnerships, while threats include clinical trial failures and competition. The company's success is closely tied to the clinical development of Bexotegrast and other pipeline assets.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • SEC Filings
  • Analyst Reports

Disclaimers:

The analysis is based on publicly available information and represents an opinion. It is not financial advice. Investors should conduct their own research before making any investment decisions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Pliant Therapeutics Inc

Exchange NASDAQ
Headquaters South San Francisco, CA, United States
IPO Launch date 2020-06-03
President, CEO & Director Dr. Bernard Coulie M.B.A., M.D., Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 171
Full time employees 171

Pliant Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases. The company's lead candidate includes bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which has completed phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325, a phase 1-ready program for treatment of the muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.